Cetuximab Plus Various Chemotherapy Regimens for Patients with KRAS Wild-Type Metastatic Colorectal Cancer

Publisher： Karger

E-ISSN： 1421-9794|61|1|51-56

ISSN： 0009-3157

Source： Chemotherapy, Vol.61, Iss.1, 2015-0, pp. : 51-56

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cetuximab Given Every 2 Weeks plus Irinotecan Is an Active and Safe Option for Previously Treated Patients with Metastatic Colorectal Cancer

By  

Chemotherapy, Vol. 56, Iss. 2, 2010-04 ,pp. : 142-146

Karger

Access to resources Recommend Favorite

Irinotecan-Cetuximab-Bevacizumab as a Salvage Treatment in Heavily Pretreated Metastatic Colorectal Cancer Patients: A Retrospective Observational Study

By  

Chemotherapy, Vol. 57, Iss. 2, 2011-03 ,pp. : 138-144

Karger

Access to resources Recommend Favorite

Comparison of the Efficacy between Pemetrexed plus Platinum and Non-Pemetrexed plus Platinum as First-Line Treatment in Patients with Wild-Type Epidermal Growth Factor Receptor Nonsquamous Non-Small Cell Lung Cancer: A Retrospective Analysis

By  

Chemotherapy, Vol. 61, Iss. 1, 2015-0 ,pp. : 41-50

Karger

Access to resources Recommend Favorite

Patients with Metastatic Colorectal Cancer and Hyperbilirubinemia Treated with FOLFIRI plus Bevacizumab as First-Line Treatment

By  

Chemotherapy, Vol. 62, Iss. 1, 2016-09 ,pp. : 80-84

Karger

Access to resources Recommend Favorite

Cisplatin plus Gemcitabine Chemotherapy in Taxane/Anthracycline-Resistant Metastatic Breast Cancer

By  

Chemotherapy, Vol. 55, Iss. 3, 2009-04 ,pp. : 155-160

Karger

Access to resources Recommend Favorite